EXAI
Exscientia plc [EXAI] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
EXAI Stock Summary
In the News
EXAI Financial details
Company Rating
-
Market Cap
585.14M
Income
-145.96M
Revenue
20.08M
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
483
Optionable
No
Shortable
Yes
Earnings
20 May 2024
P/E
-3.99
Forward P/E
-
PEG
1.46
P/S
23.53
P/B
1.54
P/C
-
P/FCF
-2.91
Quick Ratio
6.58
Current Ratio
6.67
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-0.85
EPS next Y
-
EPS next Q
-
EPS this Y
24.79%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
84.23%
Revenue last 5Y
15.89%
Revenue Q/Q
-72.64%
EPS Q/Q
-
-
-
-
-
SMA20
3.76%
SMA50
5.01%
SMA100
-
Inst Own
-
Inst Trans
-
ROA
-28%
ROE
-33%
ROC
-0.4%
Gross Margin
-28%
Oper. Margin
-740%
Profit Margin
-588%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
4.17-9.12
52W High
-46.22%
52W Low
+21%
RSI
43.84
Rel Volume
-
Avg Volume
752.14K
Volume
Perf Week
-18.79%
Perf Month
4.76%
Perf Quarter
-
Perf Half Y
-16.98%
-
-
-
-
Beta
0.784
-
-
Volatility
0.43%, 0.3%
Prev Close
0%
Price
4.84
Change
4.54%
Company Profile
- Volume Average 752.14K
- Market Capitalization 585.14M
- Employee 483
- CEO Dr. David Hallett Ph.D.
- Headquarters Oxford,GB
- IPO Date 2021-10-01
-
Website
https://www.exscientia.ai 
Exscientia plc, an artificial intelligence-driven pharmatech company, engages in discovering, designing, and developing drugs. The company offers end-to-end solution of artificial intelligence (AI) and technologies for target identification, drug candidate design, translational models, and patient selection. In addition, the company focuses on small molecule drug candidates. Its platform enables to design candidate drug molecules, as well as to provide patients with drug therapies through AI guided assessment. The company was founded in 2012 and is headquartered in Oxford, the United Kingdom.
